Effexor is a good ‘ole antidepressant commonly prescribed to help treat depression. Like most medications, it has its good points and its bad points. It’s fairly good at treating depression for people who respond to it. It has the risk of increasing the risk of hypertension, however, and it’s often difficult to get off of for some who take it. People who’ve reviewed Effexor here on Psych Central generally recommend it.

But what’s it like to be a pharmaceutical drug pusher for Effexor?

Dr. Danny Carlat tells his story helping to sell Effexor for Wyeth Pharmaceuticals for a year in today’s New York Times, before giving it up. It’s an insightful read and worth your time if you’re interested in the inner workings of the world of pharmaceutical sales.

With up to 25% of American physicians providing such “education” to other doctors, this is a common practice. Dr. Carlat’s experience is fairly typical of most physicians, although some pharmaceutical companies exert more pressure than he experienced.

Is this the ideal way to help doctors learn about new treatments for a particular disorder?

I’m sure there are better ways.

Dr. John Grohol is the CEO and founder of Psych Central. He is an author, researcher and expert in mental health online, and has been writing about online behavior, mental health and psychology issues -- as well as the intersection of technology and human behavior -- since 1992. Dr. Grohol sits on the editorial board of the journal Cyberpsychology, Behavior and Social Networking and is a founding board member and treasurer of the Society for Participatory Medicine.

Like this author?
Catch up on other posts by John M. Grohol, PsyD (or subscribe to their feed).

Comments

This post currently has no comments. You can read the comments or leave your own thoughts on our new comments page.

Trackbacks

    Last reviewed: By John M. Grohol, Psy.D. on 25 Nov 2007
    Published on PsychCentral.com. All rights reserved.